Prophylactic Ibuprofen: Effect on IUD Continuation Rates

预防性布洛芬:对宫内节育器继续使用率的影响

基本信息

  • 批准号:
    6655712
  • 负责人:
  • 金额:
    $ 15.56万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-09-25 至 2006-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Intrauterine devices (IUDs) were once a very popular birth control method in the US; in the 1970s, nearly ten percent of contracepting women used them. The rapid decline in use is due in part to the safety concerns about devices that are no longer on the market. Less than one percent of US women use today's IUDs, yet there is great potential for attracting a new population of users if the negative image of past devices can be shed and if certain unfavorable method-specific features can be mitigated. Increased bleeding and pain are the most common complaints of IUD users; together these two side effects cause up to 15 percent of women to discontinue use within the first year. Ibuprofen is commonly used to treat IUD-induced bleeding and pain, though it is not routinely provided either at the time of insertion or as a take-home medication. If new users take ibuprofen before insertion and are given a supply of ibuprofen to take home, they may avoid discomforts that might otherwise lead to early removal. The primary objective of this study is to determine whether prophylactic use of ibuprofen affects continuation rates. The study will also measure the impact ibuprofen has on the distribution of reasons for IUD removal, the number of bleeding and pain events, and the number of unscheduled clinic visits. This is a double-blind randomized controlled trial of 2,258 first-time IUD users; half of the participants will receive ibuprofen and the other half will receive an identical-appearing placebo. Women will be given their first dose 45 minutes prior to insertion and asked to take the same medication over the 3-5 days of menses for each of their next six cycles. Though the intervention component of the study lasts only six months, the two groups of women will be followed up for twelve months to compare overall discontinuation rates, reasons for removal, level of pain at insertion, incidence of post-insertion bleeding and pain events, and the number of unscheduled clinic visits. If ibuprofen is found to have a beneficial effect on continuation rates, it can become a standard feature of product labeling; because ibuprofen is inexpensive, safe, and readily available in over-the-counter form, it could ultimately improve IUD comfort for 100 million women worldwide. In the US, ibuprofen may help spur renewed interest in the most cost effective and efficacious reversible contraceptive method available.
描述(申请人提供):宫内节育器(iud)曾经是一个

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Side effects from the copper IUD: do they decrease over time?
  • DOI:
    10.1016/j.contraception.2008.11.012
  • 发表时间:
    2009-05
  • 期刊:
  • 影响因子:
    2.9
  • 作者:
    Hubacher D;Chen PL;Park S
  • 通讯作者:
    Park S
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID HUBACHER其他文献

DAVID HUBACHER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID HUBACHER', 18)}}的其他基金

Clinical trial with the levonorgestrel intrauterine system to measure changes in hemoglobin and serum ferritin among anemic women in Kenya
使用左炔诺孕酮宫内节育系统测量肯尼亚贫血妇女血红蛋白和血清铁蛋白变化的临床试验
  • 批准号:
    10688071
  • 财政年份:
    2020
  • 资助金额:
    $ 15.56万
  • 项目类别:
Clinical trial with the levonorgestrel intrauterine system to measure changes in hemoglobin and serum ferritin among anemic women in Kenya
使用左炔诺孕酮宫内节育系统测量肯尼亚贫血妇女血红蛋白和血清铁蛋白变化的临床试验
  • 批准号:
    10221015
  • 财政年份:
    2020
  • 资助金额:
    $ 15.56万
  • 项目类别:
Clinical trial with the levonorgestrel intrauterine system to measure changes in hemoglobin and serum ferritin among anemic women in Kenya
使用左炔诺孕酮宫内节育系统测量肯尼亚贫血妇女血红蛋白和血清铁蛋白变化的临床试验
  • 批准号:
    10456074
  • 财政年份:
    2020
  • 资助金额:
    $ 15.56万
  • 项目类别:
Long-acting Reversible Contraception: New Research to Reduce Unintended Pregnancy
长效可逆避孕:减少意外怀孕的新研究
  • 批准号:
    8466245
  • 财政年份:
    2011
  • 资助金额:
    $ 15.56万
  • 项目类别:
Long-acting Reversible Contraception: New Research to Reduce Unintended Pregnancy
长效可逆避孕:减少意外怀孕的新研究
  • 批准号:
    8027074
  • 财政年份:
    2011
  • 资助金额:
    $ 15.56万
  • 项目类别:
Long-acting Reversible Contraception: New Research to Reduce Unintended Pregnancy
长效可逆避孕:减少意外怀孕的新研究
  • 批准号:
    8242101
  • 财政年份:
    2011
  • 资助金额:
    $ 15.56万
  • 项目类别:
Prophylactic Ibuprofen: Effect on IUD Continuation Rates
预防性布洛芬:对宫内节育器继续使用率的影响
  • 批准号:
    6526411
  • 财政年份:
    2001
  • 资助金额:
    $ 15.56万
  • 项目类别:
Prophylactic Ibuprofen: Effect on IUD Continuation Rates
预防性布洛芬:对宫内节育器继续使用率的影响
  • 批准号:
    6370608
  • 财政年份:
    2001
  • 资助金额:
    $ 15.56万
  • 项目类别:

相似海外基金

Phase 1 and Phase 2 Clinical Trials of Cancer Chemoprevention Agents
癌症化学预防剂的1期和2期临床试验
  • 批准号:
    8339910
  • 财政年份:
    2003
  • 资助金额:
    $ 15.56万
  • 项目类别:
Phase 1 and Phase 2 Clinical Trials of Cancer Chemoprevention Agents
癌症化学预防剂的1期和2期临床试验
  • 批准号:
    7943303
  • 财政年份:
    2003
  • 资助金额:
    $ 15.56万
  • 项目类别:
PROSTATE CANCER CHEMOPREVENTION CLINICAL TRIALS
前列腺癌化学预防临床试验
  • 批准号:
    2871901
  • 财政年份:
    1997
  • 资助金额:
    $ 15.56万
  • 项目类别:
PROSTATE CANCER CHEMOPREVENTION CLINICAL TRIALS
前列腺癌化学预防临床试验
  • 批准号:
    2654231
  • 财政年份:
    1997
  • 资助金额:
    $ 15.56万
  • 项目类别:
PROSTATE CANCER CHEMOPREVENTION CLINICAL TRIALS
前列腺癌化学预防临床试验
  • 批准号:
    6150227
  • 财政年份:
    1997
  • 资助金额:
    $ 15.56万
  • 项目类别:
PROSTATE CANCER CHEMOPREVENTION CLINICAL TRIALS
前列腺癌化学预防临床试验
  • 批准号:
    2010422
  • 财政年份:
    1997
  • 资助金额:
    $ 15.56万
  • 项目类别:
PROSTATE CANCER CHEMOPREVENTION CLINICAL TRIALS
前列腺癌化学预防临床试验
  • 批准号:
    6350194
  • 财政年份:
    1997
  • 资助金额:
    $ 15.56万
  • 项目类别:
PHASE II CHEMOPREVENTION CLINICAL TRIALS - AN EXPLORATORY STUDY TO EVA-261025139
II 期化学预防临床试验 - EVA-261025139 的探索性研究
  • 批准号:
    6828865
  • 财政年份:
  • 资助金额:
    $ 15.56万
  • 项目类别:
PHASE II CHEMOPREVENTION CLINICAL TRIALS - AN EXPLORATORY STUDY TO EVA-261025139
II 期化学预防临床试验 - EVA-261025139 的探索性研究
  • 批准号:
    7329490
  • 财政年份:
  • 资助金额:
    $ 15.56万
  • 项目类别:
Phase 1 and Phase 2 Clinical Trials of Cancer Chemoprevention Agents
癌症化学预防剂的1期和2期临床试验
  • 批准号:
    7695804
  • 财政年份:
  • 资助金额:
    $ 15.56万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了